O60218 (AK1BA_HUMAN) Homo sapiens (Human)
Aldo-keto reductase family 1 member B10 UniProtKBInterProSTRINGInteractive Modelling
316 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
20 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal Structure Of AKR1B10 Complexed With NADP+ And Tolrestat | monomer | 100 | 1×NAP; 1×TOL; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and sulindac | monomer | 99.37 | 1×NAP; 1×SUZ; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and the synthetic retinoid UVI2008 | monomer | 99.37 | 1×NAP; 1×UV8; 1×EDO; | |||
| Human AKR1B10 mutant V301L complexed with NADP+ and fidarestat | monomer | 99.68 | 1×NAP; 1×FID; 1×CL; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and JF0049 | monomer | 99.37 | 1×NAP; 1×F49; 1×EDO; | |||
| Crystal structure of the methylated K125R/V301L AKR1B10 Holoenzyme | monomer | 99.37 | 1×NAP; 1×EDO; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor IDD388 | monomer | 99.37 | 1×NAP; 1×388; 1×EDO; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK319 | monomer | 99.37 | 1×NAP; 2×1WX; 1×EDO; | |||
| Crystal structure of the methylated wild-type AKR1B10 holoenzyme | monomer | 100 | 1×NAP; 1×EDO; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and JF0064 | monomer | 99.37 | 1×NAP; 1×64I; | |||
| Crystal structure of AKR1B10 complexed with NADP+ | monomer | 99.68 | 1×NAP; | |||
| Human AKR1B10 mutant V301L complexed with NADP+ and sorbinil | monomer | 99.68 | 1×NAP; 1×SBI; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK184 | monomer | 99.37 | 1×NAP; 1×MK4; 1×EDO; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK181 | monomer | 99.37 | 1×NAP; 1×W8X; 1×EDO; | |||
| Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK204 | monomer | 99.37 | 1×NAP; 1×DQP; 1×EDO; | |||
| Crystal structure of AKR1B10 complexed with NADP+ and Caffeic acid phenethyl ester | monomer | 99.68 | 1×QAP; 1×NAP; | |||
| Crystal Structure Of AKR1B10 Complexed With NADP+ And Flufenamic acid | monomer | 99.68 | 1×FLF; 1×NAP; | |||
| Crystal Structure Of AKR1B10 Complexed With NADP+ And Zopolrestat | monomer | 99.68 | 1×NAP; 1×ZST; 1×NA; | |||
| Crystal Structure Of AKR1B10 Complexed With NADP+ And Epalrestat | monomer | 99.68 | 1×EPR; 1×NAP; | |||
| Crystal structure of AKR1B10 in complex with NADP+ and Androst-4-ene-3-beta-6-alpha-diol | monomer | 100 | 1×NAP; 1×8QL; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4ga8.1.A | monomer | 0.88 | 1×NAP; | 99.68 | ||